# A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

> **NCT02413580** · PHASE3 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 49 (actual)

## Conditions studied

- Myasthenia Gravis Exacerbations

## Interventions

- **BIOLOGICAL:** IGIV-C

## Key facts

- **NCT ID:** NCT02413580
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413580, "A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02413580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*